ASTRAZENECA PLC vs NOVO NORDISK A/S, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where AZN and NVO diverge most: on return on equity, AZN reads 21.0% and NVO reads 52.8%; on return on invested capital, AZN reads 23.3% and NVO reads 51.6%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | AZN | NVO |
|---|---|---|
| Price | $160.21 | $43.07 |
| Market cap | $248.3B | $191.4B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Growth |
| P/E | 24.3 | 12.7 |
| P/B | 5.10 | 6.71 |
| P/S | 4.23 | 4.21 |
| EV/EBITDA | 17.6 | 9.0 |
| Revenue growth | +12.1% | +22.1% |
| Gross margin | 81.9% | 81.0% |
| Operating margin | 23.4% | 41.3% |
| Net margin | 17.4% | 33.1% |
| Return on equity | 21.0% | 52.8% |
| Return on assets | 9.0% | 18.9% |
| Return on invested capital | 23.3% | 51.6% |
| FCF yield | 4.7% | 4.5% |
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 0.94 | 0.80 |
| Altman Z (solvency) | 3.31 | 3.99 |
| Piotroski F (quality) | 8 / 9 | 4 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.